FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316077808> ?p ?o ?g. }

• W4316077808 endingPage "e529" @default.
• W4316077808 startingPage "e529" @default.
• W4316077808 abstract "Introduction: The Phase 3 maintenance study (FORTIFY) was a re-randomized responder withdrawal study that demonstrated efficacy and safety of risankizumab (RZB), an anti-p19 IL-23 antibody, versus (vs) withdrawal/placebo (PBO) in patients with moderate to severe Crohn’s disease (CD) who responded to RZB induction therapy. In this post-hoc analysis, we evaluated disease activity, as measured by Simple Endoscopic Score for CD (SES-CD), Crohn's Disease Activity Index (CDAI), and patient reported symptoms (PROs) of liquid stool frequency (SF) and abdominal pain score (APS), in patients who received up to 52 weeks (wks) of RZB or PBO in FORTIFY. Methods: Patients enrolled in FORTIFY achieved clinical response to IV RZB induction therapy in ADVANCE and MOTIVATE studies. Clinical response was defined as ≥30% decrease in daily SF and/or ≥30% decrease in average daily APS from induction baseline [BL])both not worse than induction BL. In FORTIFY, patients were dosed Q8W with 180 mg subcutaneous (SC) RZB, 360 mg SC RZB, or PBO. For patients who entered FORTIFY, mean SES-CD and CDAI values were calculated at induction BL and at FORTIFY Wks 0, 24 (CDAI only), and 52; mean SF and APS were calculated from patient diary data at BL of induction and at Wks 8, 16, 24, 32, 40, 48, and 52 of FORTIFY. (Figure) Results: At induction BL, mean SES-CD, CDAI, SF, and AP scores were similar between treatment groups. At FORTIFY Wk 0, disease activity scores improved from induction BL for all patients, consistent with an IV RZB induction responder population for FORTIFY. Over time, patients on RZB maintenance therapy demonstrated ongoing improvement in SES-CD and CDAI values, whereas mean SES-CD and CDAI values increased in the withdrawal/PBO group. A treatment effect was evident at Wk 52. For most timepoints throughout maintenance, patients receiving RZB showed numerically lower APS and SF (RZB 360 mg only) compared to patients in the withdrawal/PBO group. Conclusion: Across the studies, RZB therapy led to marked improvements in disease activity over time and continued to show benefit compared to withdrawal/PBO at Wk 52. The pronounced benefit of RZB over withdrawal/PBO at Wk 52 for SES-CD, an objective endoscopic endpoint, contrasts with a relative lack of differentiation at Wk 52 for the subjective SF and AP endpoints. This is likely explained by residual exposure given the long half-life and pharmacodynamic effect of RZB following induction therapy, leading to prolonged symptom improvement in patients receiving PBO in maintenance.Figure 1.: SES-CD, CDAI, SF and AP scores over time for participants enrolled in the FORTIFY maintenance study, from induction (ADVANCE/MOTIVATE) baseline through FORTIFY Week 52" @default.
• W4316077808 created "2023-01-14" @default.
• W4316077808 creator A5003778979 @default.
• W4316077808 creator A5015470174 @default.
• W4316077808 creator A5019801327 @default.
• W4316077808 creator A5021902455 @default.
• W4316077808 creator A5023978252 @default.
• W4316077808 creator A5028703130 @default.
• W4316077808 creator A5029428855 @default.
• W4316077808 creator A5041247421 @default.
• W4316077808 creator A5065557396 @default.
• W4316077808 creator A5081217869 @default.
• W4316077808 date "2022-10-01" @default.
• W4316077808 modified "2023-10-16" @default.
• W4316077808 title "S748 Risankizumab Results in Improvements in Disease Activity Scores in Patients With Crohn’s Disease: Post-Hoc Analysis of the Phase 3 Induction and Maintenance Studies" @default.
• W4316077808 doi "https://doi.org/10.14309/01.ajg.0000902188.65447.bb" @default.
• W4316077808 hasPublicationYear "2022" @default.
• W4316077808 type Work @default.
• W4316077808 citedByCount "0" @default.
• W4316077808 crossrefType "journal-article" @default.
• W4316077808 hasAuthorship W4316077808A5003778979 @default.
• W4316077808 hasAuthorship W4316077808A5015470174 @default.
• W4316077808 hasAuthorship W4316077808A5019801327 @default.
• W4316077808 hasAuthorship W4316077808A5021902455 @default.
• W4316077808 hasAuthorship W4316077808A5023978252 @default.
• W4316077808 hasAuthorship W4316077808A5028703130 @default.
• W4316077808 hasAuthorship W4316077808A5029428855 @default.
• W4316077808 hasAuthorship W4316077808A5041247421 @default.
• W4316077808 hasAuthorship W4316077808A5065557396 @default.
• W4316077808 hasAuthorship W4316077808A5081217869 @default.
• W4316077808 hasBestOaLocation W43160778081 @default.
• W4316077808 hasConcept C126322002 @default.
• W4316077808 hasConcept C142724271 @default.
• W4316077808 hasConcept C204787440 @default.
• W4316077808 hasConcept C27081682 @default.
• W4316077808 hasConcept C2776694085 @default.
• W4316077808 hasConcept C2778283404 @default.
• W4316077808 hasConcept C2779134260 @default.
• W4316077808 hasConcept C2779280984 @default.
• W4316077808 hasConcept C2780955771 @default.
• W4316077808 hasConcept C535046627 @default.
• W4316077808 hasConcept C67761136 @default.
• W4316077808 hasConcept C71924100 @default.
• W4316077808 hasConcept C90924648 @default.
• W4316077808 hasConceptScore W4316077808C126322002 @default.
• W4316077808 hasConceptScore W4316077808C142724271 @default.
• W4316077808 hasConceptScore W4316077808C204787440 @default.
• W4316077808 hasConceptScore W4316077808C27081682 @default.
• W4316077808 hasConceptScore W4316077808C2776694085 @default.
• W4316077808 hasConceptScore W4316077808C2778283404 @default.
• W4316077808 hasConceptScore W4316077808C2779134260 @default.
• W4316077808 hasConceptScore W4316077808C2779280984 @default.
• W4316077808 hasConceptScore W4316077808C2780955771 @default.
• W4316077808 hasConceptScore W4316077808C535046627 @default.
• W4316077808 hasConceptScore W4316077808C67761136 @default.
• W4316077808 hasConceptScore W4316077808C71924100 @default.
• W4316077808 hasConceptScore W4316077808C90924648 @default.
• W4316077808 hasIssue "10S" @default.
• W4316077808 hasLocation W43160778081 @default.
• W4316077808 hasLocation W43160778082 @default.
• W4316077808 hasOpenAccess W4316077808 @default.
• W4316077808 hasPrimaryLocation W43160778081 @default.
• W4316077808 hasRelatedWork W1988920656 @default.
• W4316077808 hasRelatedWork W1997244387 @default.
• W4316077808 hasRelatedWork W2029403749 @default.
• W4316077808 hasRelatedWork W2158288456 @default.
• W4316077808 hasRelatedWork W2160398099 @default.
• W4316077808 hasRelatedWork W2802339293 @default.
• W4316077808 hasRelatedWork W4205101591 @default.
• W4316077808 hasRelatedWork W4282963055 @default.
• W4316077808 hasRelatedWork W4282972491 @default.
• W4316077808 hasRelatedWork W56249736 @default.
• W4316077808 hasVolume "117" @default.
• W4316077808 isParatext "false" @default.
• W4316077808 isRetracted "false" @default.
• W4316077808 workType "article" @default.